Gushengtang Holdings Valuation Multiples

Discover revenue and EBITDA valuation multiples for Gushengtang Holdings and similar public comparables like Global Medical Response, Saudi German Health, Al-Maidan Dental Clinic, WELL Health and more.

Gushengtang Holdings Overview

About Gushengtang Holdings

Gushengtang Holdings Ltd is a traditional chinese medicine (TCM) company. Through offline medical institutions and online healthcare platforms, it provides customers with a comprehensive range of TCM healthcare services and products to address diverse medical and healthcare management needs. All of the group’s revenue is derived from the PRC.


Founded

2014

HQ

China

Employees

2.9K

Website

gstzy.cn

Financials (FY)

Revenue: $482M
EBITDA: $95M

EV

$679M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Gushengtang Holdings Financials

Gushengtang Holdings reported last fiscal year revenue of $482M and EBITDA of $95M.

In the same fiscal year, Gushengtang Holdings generated $150M in gross profit, $95M in EBITDA, and $52M in net income.


Gushengtang Holdings P&L

In the most recent fiscal year, Gushengtang Holdings reported revenue of $482M and EBITDA of $95M.

Gushengtang Holdings is profitable as of last fiscal year, with gross margin of 31%, EBITDA margin of 20%, and net margin of 11%.

See analyst estimates for Gushengtang Holdings
Last FY202320242025202620272028
Revenue$482M$345M$448M$482M
Gross Profit$150M$104M$135M$150M
Gross Margin31%30%30%31%
EBITDA$95M$64M$79M$95M
EBITDA Margin20%19%18%20%
EBIT Margin14%12%12%14%
Net Profit$52M$37M$45M$52M
Net Margin11%11%10%11%

Financial data powered by Morningstar, Inc.

Gushengtang Holdings Stock Performance

Gushengtang Holdings has current market cap of $726M, and enterprise value of $679M.


Gushengtang Holdings' stock price is $3.43.

Gushengtang Holdings has an EPS (earnings per share) of $0.25.

See more trading valuation data for Gushengtang Holdings
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$679M$726M-1.2%---$0.25

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Gushengtang Holdings Valuation Multiples

Gushengtang Holdings trades at 1.4x EV/Revenue multiple, and 7.2x EV/EBITDA.

See NTM and 2027E valuation multiples for Gushengtang Holdings

Gushengtang Holdings Financial Valuation Multiples

As of August 14, 2026, Gushengtang Holdings has market cap of $726M and EV of $679M.

Gushengtang Holdings has a P/E ratio of 13.9x.

Last FY202320242025202620272028
EV/Revenue1.4x2.0x1.5x1.4x
EV/EBITDA7.2x10.6x8.6x7.2x
EV/EBIT9.9x16.4x12.5x9.9x
EV/Gross Profit4.5x6.5x5.0x4.5x
P/E13.9x19.4x16.0x13.9x
EV/FCF9.3x13.8x12.7x9.3x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Gushengtang Holdings Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Gushengtang Holdings Margins & Growth Rates

In the most recent fiscal year, Gushengtang Holdings reported gross margin of 31%, EBITDA margin of 20%, and net margin of 11%.

See estimated margins and future growth rates for Gushengtang Holdings

Gushengtang Holdings Margins

Last FY20242025202720282029
Gross Margin31%30%31%
EBITDA Margin20%18%20%
EBIT Margin14%12%14%
Net Margin11%10%11%
FCF Margin15%12%15%

Gushengtang Holdings Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth30%8%
Gross Profit Growth30%11%
EBITDA Growth24%20%
EBIT Growth31%26%
Net Profit Growth22%15%
FCF Growth9%37%

Data powered by FactSet, Inc. and Morningstar, Inc.

Gushengtang Holdings Operational KPIs

Gushengtang Holdings' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.0M for the same period.

Access forward-looking KPIs for Gushengtang Holdings
Last FY202320242025202620272028
Revenue per Employee$0.2M---
Opex per Employee$0.0M---
S&M Expenses to Revenue11%12%12%11%
G&A Expenses to Revenue6%7%6%6%
Opex to Revenue17%18%18%17%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Gushengtang Holdings Competitors

Gushengtang Holdings competitors include Global Medical Response, Saudi German Health, Al-Maidan Dental Clinic, WELL Health, Diagnósticos da América, Hermina Hospitals, Integral Diagnostics, Garofalo Health Care, Chularat Hospital and Strata Critical Medical.

Most Gushengtang Holdings public comparables operate across Hospitals & Clinics.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Global Medical Response1.0x1.0x5.3x-
Saudi German Health1.7x1.7x6.9x8.7x
Al-Maidan Dental Clinic2.6x-12.2x-
WELL Health1.3x1.2x11.8x9.4x
Diagnósticos da América0.9x1.0x4.7x4.6x
Hermina Hospitals1.9x1.8x10.9x7.0x
Integral Diagnostics2.2x1.8x16.0x8.4x
Garofalo Health Care1.5x1.4x9.7x8.6x

This data is available for Pro users. Sign up to see all Gushengtang Holdings competitors and their valuation data.

Start Free Trial

Gushengtang Holdings VC Funding History

Before going public, Gushengtang Holdings raised $268M in total equity funding, across 3 rounds.


Gushengtang Holdings Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Mar-21Series ENew Enterprise Associates; China Feihe; Long Hill Capital; Eight Roads Ventures$38M-Gushengtang Holdings is a traditional Chinese medicine (TCM) healthcare service provider operating a hybrid model of offline clinics and online e-commerce platforms, offering comprehensive TCM services and products. Early funding included support from venture capital firms like F-Prime Capital and Eight Roads Ventures, with Eight Roads leading its Series B in 2015 and participating in subsequent rounds. The company went public on Nasdaq in 2020, raising approximately $10 million, followed by a listing on the Hong Kong Stock Exchange on December 10, 2021, raising HK$808 million (US$104 million). Eight Roads confirmed participation in prior rounds leading up to the HKEX listing, where the share price gained over 15% on debut with a market cap over HK$7 billion. For the period near the queried date, Gushengtang reported revenue of RMB 1,372 million for the year ended December 31, 2021, up 48.3% year-over-year from RMB 925 million in 2020, with adjusted net profit of RMB 157 million, up 85%. This reflects strong growth amid pandemic-related opportunities in offline acquisitions and R&D. By 2023, revenue reached RMB 2.323 billion (up 43%) with 4.3 million outpatient visits across 56 institutions. Post-IPO developments include a 2023 placing and subscription, equity buyback in 2024, and a 2026 convertible bonds placement of HKD 857 million with Boyu Capital affiliate. F-Prime and Eight Roads held ~6-8% stakes as of recent data.
Sep-17Series D-$154M-Gushengtang Holdings Limited is an investment holding company primarily engaged in providing traditional Chinese medicine (TCM) medical and health services. The company operates in China, with historical context indicating operations from at least June 2011 to September 2017, as noted in its 2022 annual report. For the first half of 2024, revenue reached about RMB 1.365 billion (up 38.4% YoY), gross profit RMB 0.401 billion, and adjusted net profit RMB 0.148 billion. Interim results for six months ended June 30, 2024, show net profit of RMB 107.3 million (up 15.1% YoY). Recent developments include stake increases by investors like Ruiyuan Fund, reaching 6.04% shareholding at a cost over HK$41 million, with total market value around RMB 8.4 billion as of recent reports.
Aug-17Series DChina Life Insurance; China Merchants Bank$77M-Gu Sheng Tang is a China-based traditional Chinese medicine clinic operator that runs clinics across multiple Chinese cities through a partnership franchise model. The company owns a 70% stake in each clinic branch while local doctors hold the remaining 30%, with Gu Sheng Tang managing back-end operations and physicians handling treatment. The company also benefits from wholesale purchasing of medical equipment across its network. In August 2017, Gu Sheng Tang secured approximately RMB1.01 billion ($150 million) in its Series D round, comprising RMB510 million in equity and RMB500 million in debt. The round included investors China Life Insurance, China Merchants Bank, Capital Risk Investment Fund, China Orient Asset Management, and two undisclosed government guidance funds. This followed earlier funding including a $25 million Series B round with Eight Roads Ventures and New Enterprise Associates in 2015, and a $70 million Series C round led by Starr Companies and Ping An Insurance in May 2016. At the time of the Series D round, Gu Sheng Tang operated 31 clinics across 13 Chinese cities. The company has since evolved significantly, with 2025 mid-year results showing operating revenue of 1.49 billion yuan, net profit of 150 million yuan, and EBITDA of approximately 270 million yuan, while membership revenue contributed 620 million yuan with an 85.8% member retention rate.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Gushengtang Holdings

When was Gushengtang Holdings founded?Gushengtang Holdings was founded in 2014.
Where is Gushengtang Holdings headquartered?Gushengtang Holdings is headquartered in China.
How many employees does Gushengtang Holdings have?As of today, Gushengtang Holdings has over 2K employees.
Is Gushengtang Holdings publicly listed?Yes, Gushengtang Holdings is a public company listed on HKEX.
What is the stock symbol of Gushengtang Holdings?Gushengtang Holdings trades under 02273 ticker.
When did Gushengtang Holdings go public?Gushengtang Holdings went public in 2021.
Who are competitors of Gushengtang Holdings?Gushengtang Holdings main competitors include Global Medical Response, Saudi German Health, Al-Maidan Dental Clinic, WELL Health, Diagnósticos da América, Hermina Hospitals, Integral Diagnostics, Garofalo Health Care, Chularat Hospital, Strata Critical Medical.
What is the current market cap of Gushengtang Holdings?Gushengtang Holdings' current market cap is $726M.
What is the current revenue of Gushengtang Holdings?Gushengtang Holdings' last fiscal year revenue is $482M.
What is the current EV/Revenue multiple of Gushengtang Holdings?Current revenue multiple of Gushengtang Holdings is 1.4x.
Is Gushengtang Holdings profitable?No, Gushengtang Holdings is not profitable.
How many companies Gushengtang Holdings has acquired to date?Gushengtang Holdings hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Gushengtang Holdings has invested to date?Gushengtang Holdings hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Gushengtang Holdings

Lists including Gushengtang Holdings

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial